Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
A Closer Look at IL-17 Inhibitors in Psoriasis : Episode 6
Opinion
Video
Safety Considerations for IL-17 Inhibitors
Panelists discuss how IL-17 inhibitors are generally well-tolerated, but common adverse effects include infections, particularly candidiasis, and potential increased suicidal ideation risk. Patients should be informed of candidiasis risk, especially with bimekizumab (Gordon, 2022), and monitored for mood changes, as IL-17s and IL-23s may impact mental health (Blauvelt, 2023). Open discussions help assess risks while ensuring treatment benefits.
Video content above is prompted by the following:
- Now let’s talk about the safety of the IL-17 inhibitor class. What is the overall safety of these agents, and what are some common adverse effects?
- How do you talk to your patients about some of the specific adverse events observed with some of these agents such as infections/candidiasis or increased risk of suicidal ideation?
- Suicidal ideation risk of IL-17s and IL-23s (Blauvelt, 2023)
- Candidiasis recurrence with bimekizumab (Gordon, 2022)
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
